Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

$3M Invested in Biological Pacemaker R&D at Cedars-Sinai Heart Institute

By Ryan Bushey | February 21, 2017

Researchers are getting closer to refining an experimental treatment for slow heartbeats.

Investigators at the Cedar-Sinai Heart Institute received a $3 million grant from the National Institutes of Health to continue research on biological pacemakers— a type of gene therapy that turns patients’ normal heart cells into pacemaker cells that regulate heart function.

“Although implantable pacemakers have helped save millions of lives since they were invented in the 1960s, biological pacemakers could result in a healthier alternative,” said Eugenio Cingolani, MD, the principal investigator in the project and the director of the Heart Institute’s Cardiogenetics Program in a statement. “Devices can malfunction or become infected, while biological pacemakers avoid such complications.”

Cingolani and his colleagues are working on a system where a specific gene called Tbx18 is delivered directly to a patient’s heart through a minimally invasive catheter-based procedure

Pacemaker cells naturally reside in the heart and produce electrical activity that spreads throughout the heart, generating heartbeats. Malfunctioning pacemaker cells can slow down the heartbeat, leading to fainting or potentially sudden death.

In this system, Tbx18 would enter the heart to transform normal heart cells into pacemaker cells to keep the organ beating steadily.

A preclinical trial featuring 12 pigs had shown the therapy was able to make a number of heart cells infected with a virus start expressing a variety of pacemaking genes over the course of a day, making the animal’s heart pump at a normal rate, according to Nature. The beating remained steady for a two-week period.

This new financing will help the scientist’s complete long-term safety and efficacy data using a clinical-grade gene delivery system that could lead to a future clinical trial.

Future applications of this approach could help children who have outgrown implanted pacemakers or patients who can’t undergo surgery because of high risks.


Filed Under: Drug Discovery

 

Related Articles Read More >

Diversity
Making diversity in clinical research more than a talking point
psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine
lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50